Evidence map›Paper›PMID 37149819›Full record

ArticleCellular and molecular life sciences : CMLS2023

Proteomics analysis of prefrontal cortex of Alzheimer's disease patients revealed dysregulated proteins in the disease and novel proteins associated with amyloid-β pathology.

Ana Montero-Calle, Raquel Coronel, María Garranzo-Asensio, Guillermo Solís-Fernández, Alberto Rábano, Vivian de Los Ríos, María Jesús Fernández-Aceñero, Marta L Mendes, Javier Martínez-Useros, Diego Megías and 4 more

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Proteomic Analysis of Endothelial Activation Induced by AdultAnimals : an open access journal from MDPI · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Protein dysregulation duringFrontiers in immunology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Ana Montero-CalleFunctional Proteomics Unit, Chronic Disease Programme (UFIEC), Instituto de Salud Carlos III, Majadahonda, E-28220, Madrid, Spain.ORCID http://orcid.org/0000-0001-5141-0454
Raquel CoronelUnidad de Regeneración Neural, Unidad Funcional de Investigación de Enfermedades Crónicas, Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.
María Garranzo-AsensioFunctional Proteomics Unit, Chronic Disease Programme (UFIEC), Instituto de Salud Carlos III, Majadahonda, E-28220, Madrid, Spain.
Guillermo Solís-FernándezFunctional Proteomics Unit, Chronic Disease Programme (UFIEC), Instituto de Salud Carlos III, Majadahonda, E-28220, Madrid, Spain.
Alberto RábanoAlzheimer Disease Research Unit, CIEN Foundation, Queen Sofia Foundation Alzheimer Center, E-28031, Madrid, Spain.
Vivian de Los RíosCentro de Investigaciones Biológicas, CSIC, E-28040, Madrid, Spain.
María Jesús Fernández-AceñeroSurgical Pathology Department, Hospital Universitario Clínico San Carlos, E-28040, Madrid, Spain.
Marta L MendesDepartment of Infection and Immunity, Luxembourg Institute of Health, L-1445, Strassen, Luxembourg.ORCID http://orcid.org/0000-0002-3528-7123
Javier Martínez-UserosTranslational Oncology Division, OncoHealth Institute, Health Research Institute-University Hospital Fundación Jiménez Díaz-Universidad Autónoma de Madrid, E-28040, Madrid, Spain.
Diego MegíasAdvanced Optical Microscopy Unit, UCCTs, Instituto de Salud Carlos III (ISCIII), E-28220, Majadahonda, Madrid, Spain.
María Teresa Moreno-CasbasInvestén-isciii, Instituto de Salud Carlos III, E-28029, Madrid, Spain.ORCID http://orcid.org/0000-0001-9061-4628
Alberto Peláez-GarcíaMolecular Pathology and Therapeutic Targets Group, La Paz University Hospital (IdiPAZ), E-28046, Madrid, Spain.
Isabel ListeUnidad de Regeneración Neural, Unidad Funcional de Investigación de Enfermedades Crónicas, Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.
Rodrigo BarderasFunctional Proteomics Unit, Chronic Disease Programme (UFIEC), Instituto de Salud Carlos III, Majadahonda, E-28220, Madrid, Spain. r.barderasm@isciii.es.ORCID http://orcid.org/0000-0003-3539-7469
Instituto de Salud Carlos III · ESCentro de Investigaciones Biológicas Margarita Salas · ESFundacion Centro De Investigacion De Enfermedades Neurologicas · ESHospital Clínico San Carlos · ESLuxembourg Institute of Health · LUUnidad Funcional de Investigación de Enfermedades Crónicas · ESUniversidad Rey Juan Carlos · ES

Funding

Instituto de Salud Carlos III PI17CIII/00045Instituto de Salud Carlos III PI20CIII/00019Ministerio de educación, cultura y deporte FPU predoctoral grantSpanish University System Margarita Salas postdoctoral grantThe Flanders Research Foundation 1193818N predoctoral fellow
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is a progressive, chronic, and neurodegenerative disease, and the most common cause of dementia worldwide. Currently, the mechanisms underlying the disease are far from being elucidated. Thus, the study of proteins involved in its pathogenesis would allow getting further insights into the disease and identifying new markers for AD diagnosis.

methodsWe aimed here to analyze protein dysregulation in AD brain by quantitative proteomics to identify novel proteins associated with the disease. 10-plex TMT (tandem mass tags)-based quantitative proteomics experiments were performed using frozen tissue samples from the left prefrontal cortex of AD patients and healthy individuals and vascular dementia (VD) and frontotemporal dementia (FTD) patients as controls (CT). LC-MS/MS analyses were performed using a Q Exactive mass spectrometer.

resultsIn total, 3281 proteins were identified and quantified using MaxQuant. Among them, after statistical analysis with Perseus (p value < 0.05), 16 and 155 proteins were defined as upregulated and downregulated, respectively, in AD compared to CT (Healthy, FTD and VD) with an expression ratio ≥ 1.5 (upregulated) or ≤ 0.67 (downregulated). After bioinformatics analysis, ten dysregulated proteins were selected as more prone to be associated with AD, and their dysregulation in the disease was verified by qPCR, WB, immunohistochemistry (IHC), immunofluorescence (IF), pull-down, and/or ELISA, using tissue and plasma samples of AD patients, patients with other dementias, and healthy individuals.

conclusionsWe identified and validated novel AD-associated proteins in brain tissue that should be of further interest for the study of the disease. Remarkably, PMP2 and SCRN3 were found to bind to amyloid-β (Aβ) fibers in vitro, and PMP2 to associate with Aβ plaques by IF, whereas HECTD1 and SLC12A5 were identified as new potential blood-based biomarkers of the disease.

Indexed as

Alzheimer DiseaseFrontotemporal DementiaNeurodegenerative DiseasesAmyloid beta-PeptidesBiomarkersChromatography, LiquidHumansPrefrontal CortexProteomicsTandem Mass Spectrometrytau ProteinsAmyloid beta-PeptidesBiomarkerstau Proteins10-plex TMTAlzheimer’s diseaseAmyloid-β interactorsBiomarkersLiquid biopsyNeurodegenerationQuantitative proteomics

Identifiers

PMID37149819
PMCPMC11073180
OpenAlexW4375846752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.